104 results about "Mimotope" patented technology

The compositions and methods include targeting peptides selective for tissue selective binding, particularly prostate and / or bone cancer, or adipose tissue. The methods may comprise targeting peptides that bind, for example, cell surface GRP78, IL-11Rα in blood vessels of bone, or prohibitin of adipose vascular tissue. These peptides may be used to induce targeted apoptosis in the presence or absence of at least one pro-apoptotic peptide. Antibodies against such targeting peptides, the targeting peptides, or their mimeotopes may be used for detection, diagnosis and / or staging of a condition, such as prostate cancer or metastatic prostate cancer.

The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may be used for detection, diagnosis and / or staging of prostate or ovarian cancer. In other embodiments, the compositions and methods concern novel type of gene therapy vector, known as adeno-associated phage (AAP). AAP are of use for targeted delivery of therapeutic agents to particular tissues, organs or cell types, such as prostate or ovarian cancer. In still other embodiments, targeting peptides selective for low-grade lipomas may be used for detection, diagnosis and targeted delivery of therapeutic agents.

Anti-glucan antibodies have been found to be protective against systemic fungal infection with C. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterised in that, when administered to a mammalian recipient, the composition elicits protective anti-glucan antibodies but does not elicit antibodies which inhibit the protective efficacy of the anti-glucan anti-bodies. The glucan may be presented on the surface of a protease-treated microbial cell or may be presented as a protein-glucan conjugate. The glucan may be substituted by a glucan mimotope, a peptidomimetic of a glucan mimotope, or nucleic acid encoding a mimotope. Anti-glucan-antibodies show broad spectrum microbicidal activity. B-glucans are preferred, particularly those containing one or more B-1,6 linkages

Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment of liver diseases and more concretely in cases of fibrosis. The said compositions can optionally include mimotopes of the said active peptides.

The invention discloses epitope for an NY-ESO-1 tumor antigen. The amino acid sequence of the mimic epitope is Ser-Leu-Leu- Met-Phe-Ile-Thr-Trp-Cys, namely SLLMFITWC; the mimic epitope can raise a CTL immunity response, can undergo a cross reaction with a natural epitope, has the characteristics of strong immunogenicity, immune tolerance breaking, strong specificity, safety, low cost, and easy synthesis and storage, and can be used to prepare tumor-therapeutic polypeptide vaccine. The invention also discloses a method for predicting the mimic epitope, which comprises steps of the establishment of a structural model of a TCR-pMHC complex, the analysis of TCR binding sites of the epitope, and the analysis of amino acid replacement of the TCR binding sites of the epitope. The method is also applicable to the computer-aided modification of CTL epitopes of other antigens, and can provide a useful tool for the design and research of therapeutic polypeptide vaccine.

The invention discloses a method for determining key amino acid of milk allergen epitope, which comprises the following steps of: synthesizing an epitope peptide section according to the primarily determined mimic epitopes area amino acid sequence, and fixing and protecting the epitope peptide section, wherein the C end covalence of the epitope peptide section is combined to an activated fibrous membrane and the N end is acetylized; taking single glycine as a negative control, reacting the synthesized amino acid sequence with polyclonal serum, and determining the main epitope of beta-milk globulin; sequentially substituting each amino acid with alanine or glycine to obtain the amino acid sequence needing to be synthesized; using the obtained amino acid sequence to synthesize the epitope peptide section, and fixing and protecting the epitope peptide section, wherein the C end covalence of the epitope peptide section is combined to the activated fibrous membrane and the N end is acetylized; and taking the single glycine as the negative control, reacting the synthesized amino acid sequence with the polyclonal serum, and determining the key amino acid in milk epitope. The method lays a foundation for the diagnosis and treatment of milk allergy and the detection of an allergen in foods and provides theoretical basis and technical support for the development of hypoallergenic milk.

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

The present invention relates to methods for preventing and treating Alzheimer's disease (AD). An Aβ42 mimotope is used for vaccination against AD. The mimotope induces the production of antibodies against Aβ42 but not against the native APP. The mimotope is functionally similar to, but not structurally identical with DAEFRH (SEQ ID NO: 1) which is a part of the naturally-occurring Aβ42 sequence.

The present invention is based on the discovery that biological peptide-based mimotopes of mannose-containing cell-wall compounds of Mycobacterium tuberculosis, specifically, ManLAM, have an anti-inflammatory effect and immunoregulator effect in animal models of inflammation. Such models include animal models of allergic peritonitis, allergic asthma and septic shock model (mice injected with LPS) and in Crohn's disease model (TNBS-induced colitis). Thus, the present invention concerns the use a molecule, particularly, an amino acid based molecule for the production of a pharmaceutical composition for the treatment of an inflammatory condition, the amino acid comprising one or more peptides characterized in that it can bind to ManLAM binding antibodies; and / or it can elicit an immune response in a subject inoculated therewith, giving rise to production of ManLAM-binding antibodies. The invention also provides pharmaceutical compositions for treating inflammatory conditions and comprising the amino acid-based molecule, as well as to methods of treatment of such conditions by administering to a subject an amount of the amino-acid based molecules.

The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and / or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.

The invention relates to a mimic eptitope peptide of BAFF-R and a DNA coding the peptide and the application of the mimic eptitope peptide in the preparation of antitumor bacterins and drugs. The mimic eptitope of 7 amino acids of BAF-R is a mimic eptitope of molecule BAFF-R with high affinity with a monoclonal antibody of BAFF-R, and is obtained through selection from a phage random display 7-peptide bank with a monoclonal antibody of BAFF-R as the antigen, wherein the sequence of the amino acids is Gly Tyr Thr Arg Trp Gly Cys. The 7-amino-acid mimic eptitope can also be used to construct a poly-peptide vaccine. The clonal inhibition rates of the phage display peptide provided by the invention are all more than 50 percent, and can specifically inhibit the combination between antibody and antigen for a larger extent, greatly improve the proliferation of mouse spleen lymphocytes without adjuvant, the mimic antigen is good in immunogenicity, as illustrated by the induced cell immune response after mice are vaccinated with the mimic antigen.

The invention discloses a CTL (Cytotoxic T Lymphocyte) epitope peptide of a foot-and-mouth disease virus type O as well as a screening method and application of the CTL epitope peptide. The CTL epitope peptide is composed of nine amino acid residues, and the amino acid sequence of the CTL epitope peptide is as follows: Ala-Thr-Arg-Val-Thr-Glu-Leu-Leu-Tyr. The epitope peptide has relatively strong combining capacity with SLA (Swineleukocyteantigen)-I proteins from various strains of swine and can induce cytotoxic immune response so as to be suitable for preparing vaccines for preventing and controlling foot-and-mouth disease viruses of various strains of swine and wide in application range. According to the invention, a CTL simulated epitope peptide of a foot-and-mouth disease virus is combined with a single-chain molecule of SLA-I of six strains of constructed swine in vitro, thus a polypeptide which can be combined with a complex can be screened through mass spectrum measurement; in addition, a simulated epitope peptide which can be induced to generate the immune response capacity of T cells is determined through ELISPOT (Enzyme-Linked Immunospot Assay) detection. The invention provides a method for screening and authenticating the CTL epitope of the foot-and-mouth disease virus in a large scale, and lays the foundation for researching and preparing a multi-epitope vaccine of a foot-and-mouth disease.

The invention discloses type A foot-and-mouth disease CTL (cytotoxic T lymphocyte) epitope peptide and a screening method thereof. The CTL epitope peptide consists of nine amino acid residues, and has an amino acid sequence of Ala-Met-Leu-Arg-Ala-Ala-Thr-Tyr-Tyr. The epitope peptide has stronger combining capability with SLA (swine leukocyte antigen)-?? proteins from pigs with different strains and causees cell toxicity immune response, and is applicable to the preparation of prevention and treatment vaccines for foot-and-mouth disease virus of pigs with various strains and wide in application range. According to the type A foot-and-mouth disease CTL epitope peptide and the screening method thereof, constructed SLA-I single-stranded molecules of pigs with six strains are utilized for in vitro combination with CTL simulated epitope peptide of foot-and-mouth disease virus, polypeptide which can be combined with complex is determined and screened by using a mass spectrum, and simulated epitope peptide which can induce the production of T cell immune response capability is determined through ELISPOT (enzyme linked immunospot assay) detection. The invention provides a method for screening and identifying a large number of foot-and-mouth disease virus CTL epitopes in the future, and lays a foundation for the development of multi-epitope vaccines for the foot-and-mouth disease of pigs.

The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain. e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.

Provided are compositions and methods for inhibiting cell growth. The cells that are targeted by the compositions and methods of the invention express an antigen, a mimotope of the antigen, or a CXCR4 chemokine receptor. The method entails administering to an individual a polynucleotide encoding an immunoglobulin Fc and an antigen expressed by the cells or a mimotope of the antigen. The method also involves administering to the individual a composition which contains a polynucleotide encoding an immunoglobulin Fc and an antagonist peptide of a CXCR4 chemokine receptor expressed by the cells. Also provided are proteins encoded by the polynucleotides.

Anti-glucan antibodies have been found to be protective against systemic fungal infection with C. albicans, but the protective efficacy can be inhibited by blocking antibodies. The invention provides an immunogenic composition comprising a glucan and a pharmaceutically acceptable carrier, characterised in that, when administered to a mammalian recipient, the composition elicits protective anti-glucan antibodies but does not elicit antibodies which inhibit the protective efficacy of the anti-glucan antibodies. The glucan may be presented on the surface of a protease-treated microbial cell or may be presented as a protein-glucan conjugate. The glucan may be substituted by a glucan mimotope, a peptidomimetic of a glucan mimotope, or nucleic acid encoding a mimotope. Anti-glucan-antibodies show broad spectrum microbicidal activity. β-glucans are preferred, particularly those containing one or more β-1,6 linkages

The invention discloses an immunochromatography test paper for testing ochratoxin A based on an M13 phage and a preparation method of the immunochromatography test paper. A test paper adsorbing layer comprises an adsorbing fiber layer, a gold-labeled antibody fiber layer, a cellulose membrane layer and a water absorbing material layer, wherein a testing blot used for showing OTA mimic epitope and blotted by the M13 phage and a contrasting blot using a goat anti-mice IgG antibody solution are arranged on the cellulose membrane layer; a gold-labeled antibody is a collaurum-labeled OTA monoclonal antibody or polyclonal antibody. According to the invention, the application of immunochromatography technique based on the M13 phage on quick OTA residue testing is realized, OTA conjugate blotted on the testing blot of a traditional test strip is replaced with the M13 phage shown with the OTA mimic epitope, harm of the OTA conjugate to a test paper producer, an experimenter and environment is avoided, and the test paper is strong in specificity and high in sensitivity during testing, and is simple and convenient to test, straightforward, accurate, low in cost, and wide in application range.

A vaccine composition for immunizing and / or protecting a mammal against an IL-31 mediated disorder is provided, wherein the composition includes: the combination of a carrier polypeptide and at least one mimotope selected from a feline IL-31 mimotope, a canine IL-31 mimotope, a horse IL-31 mimotope, and a human IL-31 mimotope; and an adjuvant. Such vaccines can be in the form of pharmaceutical compositions useful for treating or protecting mammals such as cats, dogs, horses, or humans against IL-31-mediated disorders.

The invention relates to an antigen epitope of gold staphylococcus virulence factor regulatory protein and its mimic epitope, wherein the amino acid sequence of the antigen epitope is NPTHQLFQFSASDT or SYFERYLYPIKE, the amino acid sequence of the analogue epitope is XPXHHQHXTGFT or SWFDXXLYPXXX, X is any one of the 21 known natural L-type amino acid residue or its D-type isomers. The antigen epitope or its analogue epitope can be applied in preparing staphylococcus aureus resistant medicament.

The present invention relates to peptide mimotopes of lipooligosaccharide from nontypeable Haemophilus influenzae as vaccines.

The bioinformatic screening process of simulated epitope of pathogenic microbe includes the first BLAST comparison of LCDV-1 genome sequence to screen out protective antigen protein candidate gene TK and ORF29; the subsequent hydrophobicity, hydrophilicity, antigenicity and transmembrane structure analysis of these two gene expressed proteins and synthesizing 12 kinds of structural analysis results; and final presumption of unknown LCDV-cn corresponding simulated epitopes with I>0 sequences based on the comprehensive antigen index formula. The obtained simulated epitopes are further artificially synthesized and the immunoreactivity of various simulated epitopes are inspected through competitive enzyme-linked immune analysis. The present invention makes best utilization of rich nucleic acid and protein sequence resource to capture the simulated epitope of unknown pathogenic microbe antigen protein through specific bioinformatic analysis.

The present invention provides a method for producing a vaccine against cancerous disease, and the vaccine itself. This method involves first using one or more antibodies that are specifically effective against one or more antigens specially expressed by the tumor cells to select one or more mimotopes of said antigens from a phage peptide library. To obtain the vaccine, said mimotopes are conjugated to a macromolecular carrier singly or multiply in the form of their mono-, di-, tri- or oligomers. When administered, the inventively produced vaccine leads to a humoral immune response and thus to the formation of an active immunity as a consequence of vaccination.

The present invention discloses a simulation epitope of 12 amino acids of human cell B specificity expression membrane molecule CD 20 and its polypeptide epitope vaccine constructed by using said simulation spitope. Said invention also provides a method for screening simulation epitope of CD 20 molecule by using Rituximab as ligand, and provides its amino acid sequence, Gln-Asp-Lys-Leu-Th-Gln-Try-Pro-Lys-Try-Leu-Glu. Said invention also provides a method for chemically-synthesizing simulation epitope of 12 amino acids and making it be chemically-coupled with keyhole limpet hemo cyanin (KLH) to obtain the successfully-constructed vaccine. Besides, said invention also provides the concrete application of said vaccine.

The invention relates to staphylococcus aureus FnBPA-A protein mimic epitope peptides having immunizing protection, a mimic epitope peptide composition, and applications of the mimic epitope peptides and the mimic epitope peptide composition. Two immunoprotective mimic epitope peptides provided by the invention have the amino acid sequences respectively shown in SEQ ID NO:1 and SEQ ID NO:2, the mimic epitope peptide composition consists of two polypeptides shown in SEQ ID NO:1 and SEQ ID NO:2, and the mass ratio of the polypeptide shown in SEQ ID NO:1 to the polypeptide shown in SEQ ID NO:2 is 2 to 1. Experiment animal immunoprotective tests show that the two mimic epitope peptides can stimulate a body to produce high-level specific antibodies and have a certain degree of immunizing protection; moreover, the mimic epitope peptide composition has the immunoprotective effect on staphylococcus aureus infection better than that of an FnBPA-A holoprotein. Therefore, the mimic epitope peptides and the composition thereof can be used as effective components for development of multi-epitope vaccines of staphylococcus aureus and prevention of cow mastitis caused by staphylococcus aureus.

The invention discloses a tumor antigen TRAG-3 mimic epitope peptide and an application thereof. The mimic epitope peptide comprises an amino acid sequence shown by Ile-Leu-Leu-Arg-Asp-Ala-Gly-Leu-Val, wherein the fifth Asp is D-Asp or the sixth Ala is D-Ala. The mimic epitope peptide has the advantages of better enzymic degradation resistant stability compared with TRAG-3 natural epitope peptide, stronger appetency compared with HLA-A2.1, and stronger CTL specific killing effect compared with TRAG-3 positive tumor cells, can be used for preparing polypeptide vaccine for treating the TRAG-3 positive tumor cells, and has good development and application prospect in the immunotherapy filed.

Peptidyl sequences, called mimotopes, are disclosed which mimic the binding site of the broadly neutralizing human monoclonal antibody, 2G12, specific for the HIV protein gp120. The mimotopes are identified from a chimeric protein III (pIII) phage display library, each phage containing an additional random 15 amino acids near the N-terminus of pIII. Immunological conjugates of HIV-specific mimotopes that are useful for vaccination against HIV infection are disclosed. Methods for using the mimotopes and their immunological conjugates as part of an HIV vaccine regime, as well as diagnostic tools to perform viral assays, are also disclosed.

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.